Superparamagnetic iron oxide nanoparticles: Promises for diagnosis and treatment of cancer

International Journal of Molecular Epidemiology and Genetics

Volumn 2, Issue 4, 2011, Pages 367-390

  Laurent, Sophie ^a   Mahmoudi, Morteza ^b,c  

^a UNIVERSITY OF MONS   (Belgium)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anticancer drugs; Cancer; Chemotherapy; Coatings; Controlled drug release; Nanoparticle; Nanoscience; Nanotechnology; Radiotherapy; Spions; Superparamagnetic iron oxide nanoparticles; Surfaces; Targeted drug delivery; Thermotherapy; Tumor

Indexed keywords

ACRYLIC ACID; ALBUMIN; ALGINIC ACID; BETA CYCLODEXTRIN; CHITOSAN; CYSTEINE; DEXTRAN; DOPAMINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MACROGOL; NANOCRYSTAL; PACLITAXEL; PHOSPHONIC ACID DERIVATIVE; POLYCAPROLACTONE; POLYETHYLENEIMINE; POLYLACTIC ACID; POLYSACCHARIDE; POLYVINYL ALCOHOL; SILANE DERIVATIVE; SUCCIMER; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CELL STRAIN MCF 7; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG STABILITY; ENCAPSULATION; GLIOBLASTOMA; HUMAN; HYPERTHERMIA; MAGNETIC FIELD; MASS SPECTROMETRY; NANOBIOTECHNOLOGY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRECIPITATION; RADIATION DOSE; SYNTHESIS;

EID: 83755178523     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (237)

1. Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB. Cancer is a Preventable Disease that Requires Major Lifestyle Changes. Pharm Res 2008; 25: 2097-116.
2. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy. Advanced Drug Delivery Reviews 2011; 63: 24-46.
3. Means GE, Feeney RE. Chemical Modifications of Proteins: History and Applications. Bioconjugate Chemistry 1990; 1: 2-12.
4. Chau Y, Dang NM, Tan FE, Langer R. Investigation of targeting mechanism of new dextranpeptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinaseoverexpressing tumor xenograft model. Journal of Pharmaceutical Sciences 2006; 95: 542-51.
5. Gregoriadis G. Engineering liposomes for drug delivery: Progress and problems. Trends in Biotechnology 1995; 13: 527-37.
6. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. Journal of Pharmaceutical Sciences 2003; 92: 1343-55.
7. Rosler A, Vandermeulen GWM, Klok HA. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Advanced Drug Delivery Reviews 2001; 53: 95-108.
8. Wu GH, Milkhailovsky A, Khant HA, Fu C, Chiu W, Zasadzinski JA. Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. Journal of the American Chemical Society 2008; 130: 8175-7.
9. Son SJ, Bai X, Lee SB. Inorganic hollow nanoparticles and nanotubes in nanomedicine. Part 1. Drug/gene delivery applications. Drug Discovery Today 2007; 12: 650-6.
10. Akerman ME, Chan WCW, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 12617-21.
11. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chemical Reviews 1999; 99: 3181-98.
12. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today 2005; 10: 1451-8.
13. Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nature Biotechnology 2001; 19: 1029-34.
14. Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Advanced Drug Delivery Reviews 2002; 54: 135-47.
15. Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discovery Today 2002; 7: 569-79.
16. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Advanced Drug Delivery Reviews 2001; 53: 321-39.
17. Santini JT, Cima MJ, Langer R. A controlledrelease microchip. Nature 1999; 397: 335-8.
18. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nature Biotechnology 2003; 21: 1184-91.
19. Grayson ACR, Choi IS, Tyler BM, Wang PP, Brem H, Cima MJ, Langer R. Multi-pulse drug delivery from a resorbable polymeric microchip device. Nature Materials 2003; 2: 767-72.
20. Razzacki SZ, Thwar PK, Yang M, Ugaz VM, Burns MA. Integrated microsystems for controlled drug delivery. Advanced Drug Delivery Reviews 2004; 56: 185-98.
21. Collins JM. PHARMACOLOGIC RATIONALE FOR REGIONAL DRUG DELIVERY. Journal of Clinical Oncology 1984; 2: 498-504.
22. Egan TD. Intravenous drug delivery systems: Toward an intravenous "vaporizer". Journal of Clinical Anesthesia 1996; 8: S8-S14.
23. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncology 2003; 4: 277-83.
24. Edwards DA, Hanes J, Caponetti G, Hrkach J, BenJebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868-71.
25. Prausnitz MR, Bose VG, Langer R, Weaver JC. ELECTROPORATION OF MAMMALIAN SKIN-A MECHANISM TO ENHANCE TRANSDERMAL DRUG-DELIVERY. Proceedings of the National Academy of Sciences of the United States of America 1993; 90: 10504-8.
26. Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: A novel approach to transdermal drug delivery. Journal of Pharmaceutical Sciences 1998; 87: 922-5.
27. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nature Reviews Drug Discovery 2004; 3: 115-24.
28. Illum L. Nasal drug delivery: new developments and strategies. Drug Discovery Today 2002; 7: 1184-9.
29. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release. 2003; 87: 187-98.
30. Brannonpeppas L. NOVEL VAGINAL DRUGRELEASE APPLICATIONS. Advanced Drug Delivery Reviews 1993; 11: 169-77.
31. Loftssona T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Advanced Drug Delivery Reviews 1999; 36: 59-79.
32. Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-Recent advances. Progress in Retinal and Eye Research 1998; 17: 33-58.
33. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block copolymers as injectable drugdelivery systems. Nature 1997; 388: 860-2.
34. Li F, Liu WG, De Yao K. Preparation of oxidized glucose-crosslinked N-alkylated chitosan membrane and in vitro studies of pH-sensitive drug delivery behaviour. Biomaterials 2002; 23: 343-7.
35. Mitragotri S. Innovation-Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nature Reviews Drug Discovery 2005; 4: 255-60.
36. Liu YY, Miyoshi H, Nakamura M. Encapsulated ultrasound microbubbles: Therapeutic application in drug/gene delivery. Journal of Controlled Release 2006; 114: 89-99.
37. Ng KY, Liu Y. Therapeutic ultrasound: Its application in drug delivery. Medicinal Research Reviews 2002; 22: 204-23.
38. Lubbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. Journal of Surgical Research 2001; 95: 200-6.
39. Polyak B, Friedman G. Magnetic targeting for site-specific drug delivery: applications and clinical potential. Expert Opinion on Drug Delivery 2009; 6: 53-70.
40. Sahoo SK, Labhasetwar V. Nanotech approaches to delivery and imaging drug. Drug Discovery Today 2003; 8: 1112-20.
41. Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discovery Today 2003; 8: 259-66.
42. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7.
43. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnology 1997; 15: 871-5.
44. Mahmoudi M, Serpooshan V, Laurent S. Engineered nanoparticles for biomolecular imaging. Nanoscale 2011; 3: 3007-29.
45. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, Boutry S, Simchi A, Shane Journeay W, Subramani K, Laurent S. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chemical Reviews 2011; 111: 253-80.
46. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005; 26: 3995-4021.
47. Mahmoudi M, Milani AS, Stroeve P, Arbab SA. Superparamagnetic Iron Oxide Nanoparticles: Synthesis, Surface Engineering, Cytotoxicity and Biomedical Applications; Nova Science Publisher; New York, 2011; ISBN: 978-1-61668-964-3.
48. Mahmoudi M, Simchi A, Imani M, Milani AS, Stroeve P. Optimal design and characterization of superparamagnetic iron oxide nanoparticles coated with polyvinyl alcohol for targeted delivery and imaging. Journal of Physical Chemistry B 2008; 112: 14470-81.
49. Mahmoudi M, Sahraian MA, Shokrgozar MA, Laurent S. Superparamagnetic iron oxide nanoparticles: Promises for diagnosis and treatment of multiple sclerosis. ACS Chemical Neuroscience 2011; 2: 118-40.
50. Mahmoudi M, Amiri H, Shokrgozar MA, Sasanpour P, Rashidian B, Laurent S, Casula MF, Lascialfari A. Raman active jagged-shaped gold-coated magnetic particles as a novel multimodal nanoprobe. Chemical Communications 2011; 47: 10404-6.
51. Mahmoudi M, Simchi A, Imani M. Recent advances in surface engineering of superparamagnetic iron oxide nanoparticles for biomedical applications. Journal of the Iranian Chemical Society 2010; 7: S1-S27.
52. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN. Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological Applications. Chemical Reviews 2008; 108: 2064-110.
53. Laurent S, Boutry S, Mahieu I, Vander Elst L, Muller RN. Iron Oxide Based MR Contrast Agents: from Chemistry to Cell Labeling. Current Medicinal Chemistry 2009; 16: 4712-27.
54. Fukukura Y, Kamiyama T, Takumi K, Shindo T, Higashi R, Nakajo M. Comparison of ferucarbotran-enhanced fluid-attenuated inversionrecovery echo-planar, T2-weighted turbo spinecho, T2*-weighted gradient-echo, and diffusion-weighted echo-planar imaging for detection of malignant liver lesions. Journal of Magnetic Resonance Imaging 2010; 31: 607-16.
55. Saito K, Sugimoto K, Nishio R, Araki Y, Moriyasu F, Kakizaki D, Tokuuye K. Perfusion study of liver lesions with superparamagnetic iron oxide: distinguishing hepatocellular carcinoma from focal nodular hyperplasia. Clinical imaging 2009; 33: 447-53.
56. Santoro L, Grazioli L, Filippone A, Grassedonio E, Belli G, Colagrande S. Resovist enhanced MR imaging of the liver: Does quantitative assessment help in focal lesion classification and characterization? Journal of Magnetic Resonance Imaging 2009; 30: 1012-20.
57. Meier R, Henning TD, Boddington S, Tavri S, Arora S, Piontek G, Rudelius M, Corot C, Daldrup-Link HE. Breast Cancers: MR Imaging of Folate-Receptor Expression with the Folate-Specific Nanoparticle P1133. Radiology 2010; 255: 527-35.
58. Radermacher KA, Boutry S, Laurent S, Elst LV, Mahieu I, Bouzin C, Magat J, Gregoire V, Feron O, Muller RN, Jordan BF, Gallez B. Iron oxide particles covered with hexapeptides targeted at phosphatidylserine as MR biomarkers of tumor cell death. Contrast Media & Molecular Imaging 2010; 5: 258-67.
59. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, Chin SF, Sherry AD, Boothman DA, Gao J. Multifunctional Polymeric Micelles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems. Nano Letters 2006; 6: 2427-30.
60. Winter PM, Caruthers SD, Allen JS, Cai K, Williams TA, Lanza GM, Wickline SA. Molecular imaging of angiogenic therapy in peripheral vascular disease with ανβ3-integrin-targeted nanoparticles. Magnetic Resonance in Medicine 2010; 64: 369-76.
61. Park J, An K, Hwang Y, Park JG, Noh HJ, Kim JY, Park JH, Hwang NM, Hyeon T. Ultra-largescale syntheses of monodisperse nanocrystals. Nat Mater 2004; 3: 891-5.
62. Mahmoudi M, Milani AS, Stroeve P. Synthesis, surface architecture and biological response of superparamagnetic iron oxide nanoparticles for application in drug delivery: a review. International Journal of Biomedical Nanoscience and Nanotechnology 2010; 1: 164-201.
63. Wang X, Zhuang J, Peng Q, Li Y. A general strategy for nanocrystal synthesis. Nature 2005; 437: 121-4.
64. Khan Y, Durrani SK, Siddique M, Mehmood M. Hydrothermal synthesis of alpha Fe2O3 nanoparticles capped by Tween-80. Materials Letters 2011; 65: 2224-7.
65. Sun S, Zeng H, Robinson DB, Raoux S, Rice PM, Wang SX, Li G. Monodisperse MFe2O4 (M = Fe, Co, Mn) Nanoparticles. Journal of the American Chemical Society 2004; 14: 273-9.
66. Chikate RC, Jun KW, Rode CV. Nonaqueous synthesis and characterization of capped-± Fe2O3 nanoparticles from iron(III) hydroxyoleate precursor. Polyhedron 2008; 27: 933-8.
67. Dresco PA, Zaitsev VS, Gambino RJ, Chu B. Preparation and Properties of Magnetite and Polymer Magnetite Nanoparticles. Langmuir. 1999; 15: 1945-51.
68. Narita A, Naka K, Chujo Y. Facile control of silica shell layer thickness on hydrophilic iron oxide nanoparticles via reverse micelle method. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2009; 336: 46-56.
69. Lu A-H, Salabas EL, Schüth F. Magnetic Nanoparticles: Synthesis, Protection, Functionalization, and Application. Angewandte Chemie International Edition 2007; 46: 1222-44.
70. Shen L, Stachowiak A, Fateen S-EK, Laibinis PE, Hatton TA. Structure of Alkanoic Acid Stabilized Magnetic Fluids. A Small-Angle Neutron and Light Scattering Analysis. Langmuir 2000; 17: 288-99.
71. Boyer C, Whittaker MR, Bulmus V, Liu J, Davis TP. The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications. NPG Asia Materials 2010; 2: 23-30.
72. Hong RY, Feng B, Chen LL, Liu GH, Li HZ, Zheng Y, Wei DG. Synthesis, characterization and MRI application of dextran-coated Fe3O4 magnetic nanoparticles. Biochemical Engineering Journal 2008; 42: 290-300.
73. Saboktakin MR, Tabatabaie RM, Maharramov A, Ramazanov MA. A synthetic macromolecule as MRI detectable drug carriers: Aminodextran-coated iron oxide nanoparticles. Carbohydrate Polymers 2010; 80: 695-8.
74. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Advanced Drug Delivery Reviews 2006; 58: 1471-504.
75. Gomez-Lopera SA, Arias JL, Gallardo V, Delgado AV. Colloidal Stability of Magnetite/ Poly(lactic acid) Core/Shell Nanoparticles. Langmuir 2006; 22: 2816-21.
76. Arias JL, Gallardo V, Oacute, Mez-Lopera SA, Delgado AV. Loading of 5-Fluorouracil to Poly (ethyl-2-cyanoacrylate) Nanoparticles with a Magnetic Core. Journal of Biomedical Nanotechnology 2005; 1: 214-23.
77. Molday RS, Mackenzie D. Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. Journal of Immunological Methods 1982; 52: 353-67.
78. Lunov O, Syrovets T, Büchele B, Jiang X, Röcker C, Tron K, Nienhaus GU, Walther P, Mailänder V, Landfester K, Simmet T. The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun Nterminal kinase-mediated apoptosis in human macrophages. Biomaterials 2010; 31: 5063-71.
79. Mouaziz H, Veyret R, Theretz A, Ginot F, Ric, Elaissari A. Aminodextran Containing Magnetite Nanoparticles for Molecular Biology Applications: Preparation and Evaluation. Journal of Biomedical Nanotechnology 2009; 5: 172-81.
80. Paul KG, Frigo TB, Groman JY, Groman EV. Synthesis of Ultrasmall Superparamagnetic Iron Oxides Using Reduced Polysaccharides. Bioconjugate Chemistry 2004; 15: 394-401.
81. Kampert E, Janssen FFBJ, Boukhvalov DW, Russcher JC, Smits JMM, de Gelder R, de Bruin B, Christianen PC, Zeitler U, Katsnelson MI, Maan JC, Rowan AE. Ligand-Controlled Magnetic Interactions in Mn4 Clusters. Inorganic Chemistry. 2009; 48: 11903-8.
82. Chu WJ. Surface properties of superparamagnetic iron oxide MR contrast agents: Ferumoxides, ferumoxtran, ferumoxsil. Magnetic Resonance Imaging 1995; 13: 675-91.
83. Carmen Bautista M, Bomati-Miguel O, del Puerto Morales M, Serna CJ, Veintemillas-Verdaguer S. Surface characterisation of dextran-coated iron oxide nanoparticles prepared by laser pyrolysis and coprecipitation. Journal of Magnetism and Magnetic Materials 2005; 293: 20-7.
84. Anzai Y, McLachlan S, Morris M, Saxton R, Lufkin RB. Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck. American Journal of Neuroradiology 1994; 15: 87-94.
85. Bourrinet P, Bengele HH, Bonnemain B, Dencausse A, Idee JM, Jacobs PM, Lewis JM. Preclinical Safety and Pharmacokinetic Profile of Ferumoxtran-10, an Ultrasmall Superparamagnetic Iron Oxide Magnetic Resonance Contrast Agent. Investigative Radiology 2006; 41: 313-24.
86. Bellin MF, Beigelman C, Precetti-Morel S. Iron oxide-enhanced MR lymphography: initial experience. European Journal of Radiology 2000; 34: 257-64.
87. Clement O, Siauve N, Cuénod CA, Frija G. Liver Imaging With Ferumoxides (Feridex(R)): Fundamentals, Controversies, and Practical Aspects. Topics in Magnetic Resonance Imaging 1998; 9: 167-82.
88. Mornet S, Portier J, Duguet E. A method for synthesis and functionalization of ultrasmall superparamagnetic covalent carriers based on maghemite and dextran. Journal of Magnetism and Magnetic Materials 2005; 293: 127-34.
89. Catherine CB, Adam SGC. Functionalisation of magnetic nanoparticles for applications in biomedicine. Journal of Physics D: Applied Physics 2003; 36: R198.
90. Wapner K, Grundmeier G. Spectroscopic analysis of the interface chemistry of ultra-thin plasma polymer films on iron. Surface and Coatings Technology 2005; 200: 100-3.
91. Love JC, Estroff LA, Kriebel JK, Nuzzo RG, Whitesides GM. Self-Assembled Monolayers of Thiolates on Metals as a Form of Nanotechnology. Chemical Reviews 2005; 105: 1103-70.
92. Chen Y, Liu W, Ye C, Yu L, Qi S. Preparation and characterization of self-assembled alkanephosphate monolayers on glass substrate coated with nano-TiO2 thin film. Materials Research Bulletin 2001; 36: 2605-12.
93. Arbab AS, Wilson LB, Ashari P, Jordan EK, Lewis BK, Frank JA. A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. NMR in Biomedicine 2005; 18: 383-9.
94. Kim DK, Mikhaylova M, Wang FH, Kehr J, Bjelke B, Zhang Y, Tsakalakos T, Muhammed Mamoun. Starch-Coated Superparamagnetic Nanoparticles as MR Contrast Agents. Chemistry of Materials 2003; 15: 4343-51.
95. Lee HS, Hee Kim E, Shao H, Kook Kwak B. Synthesis of SPIO-chitosan microspheres for MRI-detectable embolotherapy. Journal of Magnetism and Magnetic Materials 2005; 293: 102-5.
96. Huang HY, Shieh YT, Shih CM, Twu YK. Magnetic chitosan/iron (II, III) oxide nanoparticles prepared by spray-drying. Carbohydrate Polymers 2010; 81: 906-10.
97. Reimer P, Marx C, Rummeny EJ, Müller M, Lentschig M, Balzer T, Dietl KH, Sulkowski U, Berns T, Shamsi K, Peters PE. SPIO-enhanced 2D-TOF MR angiography of the portal venous system: Results of an intraindividual comparison. Journal of Magnetic Resonance Imaging 1997; 7: 945-9.
98. Holgado MA, Alvarez-Fuentes J, Fernández-Arévalo M, Arias JL. Possibilities of Poly(D,Llactide-co-glycolide) in the Formulation of Nanomedicines Against Cancer. Current Drug Targets 2011; 12: 1096-111.
99. Hu FX, Neoh KG, Kang ET. Synthesis and in vitro anti-cancer evaluation of tamoxifenloaded magnetite/PLLA composite nanoparticles. Biomaterials 2006; 27: 5725-33.
100. Bulte JWM, Cuyper M, Despres D, Frank JA. Preparation, relaxometry, and biokinetics of PEGylated magnetoliposomes as MR contrast agent. Journal of Magnetism and Magnetic Materials 1999; 194: 204-9.
101. Shultz MD, Calvin S, Fatouros PP, Morrison SA, Carpenter EE. Enhanced ferrite nanoparticles as MRI contrast agents. Journal of Magnetism and Magnetic Materials 2007; 311: 464-8.
102. Ai H, Flask C, Weinberg B, Shuai XT, Pagel MD, Farrell D, Duerk J, Gao J. Magnetite-Loaded Polymeric Micelles as Ultrasensitive Magnetic-Resonance Probes. Advanced Materials 2005; 17: 1949-52.
103. Li Z, Wei L, Gao MY, Lei H. One-Pot Reaction to Synthesize Biocompatible Magnetite Nanoparticles. Advanced Materials 2005; 17: 1001-5.
104. [] Sun C, Veiseh O, Gunn J, Fang C, Hansen S, Lee D, Sze R, Ellenbogen RG, Olson J, Zhang M. In Vivo MRI Detection of Gliomas by Chlorotoxin-Conjugated Superparamagnetic Nanoprobes Small 2008; 4: 372-9.
105. Dodd CH, Hsu HC, Chu WJ, Yang P, Zhang HG, Mountz Jr JD, Zinn K, Forder J, Josephson L, Weissleder R, Mountz JM, Mountz JD. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. Journal of Immunological Methods 2001; 256: 89-105.
106. Sun C, Sze R, Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. Journal of Biomedical Materials Research Part A 2006; 78: 550-7.
107. Zhang Y, Zhang J. Surface modification of monodisperse magnetite nanoparticles for improved intracellular uptake to breast cancer cells. Journal of Colloid and Interface Science 2005; 283: 352-7.
108. Xu C, Xu K, Gu H, Zheng R, Liu H, Zhang X, Guo Z, Xu B. Dopamine as A Robust Anchor to Immobilize Functional Molecules on the Iron Oxide Shell of Magnetic Nanoparticles. Journal of the American Chemical Society 2004; 126: 9938-9.
109. Raty JK, Liimatainen T, Wirth T, Airenne KJ, Ihalainen TO, Huhtala T, Hamerlynck E, Vihinen-Ranta M, Närvänen A, Ylä-Herttuala S, Hakumäki JM. Magnetic resonance imaging of viral particle biodistribution in vivo. Gene Ther 2006; 13: 1440-6.
110. Schellenberger E, Schnorr J, Reutelingsperger C, Ungethüm L, Meyer W, Taupitz M, Hamm B. Linking Proteins with Anionic Nanoparticles via Protamine: Ultrasmall Protein-Coupled Probes for Magnetic Resonance Imaging of Apoptosis. Small 2008; 4: 225-30.
111. Hodenius MAJ, Niendorf T, Krombach GA, Richtering W, Eckert T, Lueken H, Speldrich M, Günther RW, Baumann M, Soenen SJ, De Cuyper M, Schmitz-Rode T. Synthesis, Physicochemical Characterization and MR Relaxometry of Aqueous Ferrofluids. Journal of Nanoscience and Nanotechnology 2008; 8: 2399-409.
112. Racuciu M, Creanga D, Airinei A. Citric-acidcoated magnetite nanoparticles for biological applications. The European Physical Journal E: Soft Matter and Biological Physics 2006; 21: 117-21.
113. Sahoo Y, Pizem H, Fried T, Golodnitsky D, Burstein L, Sukenik CN, Markovich G. Alkyl Phosphonate/Phosphate Coating on Magnetite Nanoparticles: A Comparison with Fatty Acids. Langmuir 2001; 17: 7907-11.
114. White MA, Johnson JA, Koberstein JT, Turro NJ. Toward the Syntheses of Universal Ligands for Metal Oxide Surfaces: Controlling Surface Functionality through Click Chemistry. Journal of the American Chemical Society 2006; 128: 11356-7.
115. Auernheimer J, Zukowski D, Dahmen C, Kantlehner M, Enderle A, Goodman SL, Kessler H. Titanium Implant Materials with Improved Biocompatibility through Coating with Phosphonate-Anchored Cyclic RGD Peptides. ChemBioChem 2005; 6: 2034-40.
116. Mohapatra S, Pramanik P. Synthesis and stability of functionalized iron oxide nanoparticles using organophosphorus coupling agents. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2009; 339: 35-42.
117. Barja BC, Herszage J, dos Santos Afonso M. Iron(III)-phosphonate complexes. Polyhedron 2001; 20: 1821-30.
118. Fauconnier N, Pons JN, Roger J, Bee A. Thiolation of Maghemite Nanoparticles by Dimercaptosuccinic Acid. Journal of Colloid and Interface Science 1997; 194: 427-33.
119. Halbreich A, Roger J, Pons JN, Geldwerth D, Da Silva MF, Roudier M, Bacri JC. Biomedical applications of maghemite ferrofluid. Biochimie 1998; 80: 379-90.
120. Barnakov YA, Yu MH, Rosenzweig Z. Manipulation of the Magnetic Properties of Magnetite-Silica Nanocomposite Materials by Controlled Stober Synthesis. Langmuir 2005; 21: 7524-7.
121. Im SH, Herricks T, Lee YT, Xia Y. Synthesis and characterization of monodisperse silica colloids loaded with superparamagnetic iron oxide nanoparticles. Chemical Physics Letters 2005; 401: 19-23.
122. [] Galvin P, Thompson D, Ryan K, McCarthy A, Moore AC, Burke CS, Dyson M, Maccraith BD, Gun'ko YK, Byrne MT, Volkov Y, Keely C, Keehan E, Howe M, Duffy C, Macloughlin R. Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. Cellular and Molecular Life Sciences 2011; [Epub ahead of print].
123. Sun EY, Josephson L, Kelly KA, Weissleder R. Development of Nanoparticle Libraries for Biosensing. Bioconjugate Chemistry 2005; 17: 109-13.
124. Jung HI, Kettunen MI, Davletov B, Brindle KM. Detection of Apoptosis Using the C2A Domain of Synaptotagmin I. Bioconjugate Chemistry 2004; 15: 983-7.
125. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magnetic Resonance in Medicine 2003; 49: 403-8.
126. Go KG, Bulte JWM, de Ley L, The TH, Kamman RL, Hulstaert CE, Blaauw EH, Ma LD. Our approach towards developing a specific tumourtargeted MRI contrast agent for the brain. European Journal of Radiology 1993; 16: 171-5.
127. Johansson LO, Bjørnerud A, Ahlström HK, Ladd DL, Fujii DK. A targeted contrast agent for magnetic resonance imaging of thrombus: Implications of spatial resolution. Journal of Magnetic Resonance Imaging 2001; 13: 615-8.
128. Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in Vivo by using transferrin receptor pathways. Magnetic Resonance in Medicine 1998; 40: 236-42.
129. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med 2001; 7: 1241-4.
130. Weissleder R, Lee AS, Fischman AJ, Reimer P, Shen T, Wilkinson R, Callahan RJ, Brady TJ. Polyclonal human immunoglobulin G labeled with polymeric iron oxide: antibody MR imaging. Radiology 1991; 181: 245-9.
131. Toma A, Otsuji E, Kuriu Y, Okamoto K, Ichikawa D, Hagiwara A, Ito H, Nishimura T, Yamagishi H. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma. Br J Cancer 2005; 93: 131-6.
132. Bulte JWM, Zhang SC, van Gelderen P, Herynek V, Jordan EK, Duncan ID, Frank JA. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: Magnetic resonance tracking of cell migration and myelination. Proceedings of the National Academy of Sciences 1999; 96: 15256-61.
133. van Everdingen KJ, Enochs WS, Bhide PG, Nossiff N, Papisov M, Bogdanov A Jr, Brady TJ, Weissleder R. Determinants of in vivo MR imaging of slow axonal transport. Radiology 1994; 193: 485-91.
134. Hogemann D, Josephson L, Weissleder R, Basilion JP. Improvement of MRI Probes To Allow Efficient Detection of Gene Expression. Bioconjugate Chemistry 2000; 11: 941-6.
135. Josephson L, Tung CH, Moore A, Weissleder R. High-Efficiency Intracellular Magnetic Labeling with Novel Superparamagnetic-Tat Peptide Conjugates. Bioconjugate Chemistry 1999; 10: 186-91.
136. Montet X, Weissleder R, Josephson L. Imaging Pancreatic Cancer with a Peptide Nanoparticle Conjugate Targeted to Normal Pancreas. Bioconjugate Chemistry 2006; 17: 905-11.
137. Tsourkas A, Shinde-Patil VR, Kelly KA, Patel P, Wolley A, Allport JR, Weissleder R. In Vivo Imaging of Activated Endothelium Using an Anti-VCAM-1 Magnetooptical Probe. Bioconjugate Chemistry 2005; 16: 576-81.
138. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L. Multivalent Effects of RGD Peptides Obtained by Nanoparticle Display. Journal of Medicinal Chemistry 2006; 49: 6087-93.
139. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of Vascular Adhesion Molecule-1 Expression Using a Novel Multimodal Nanoparticle. Circulation Research 2005; 96: 327-36.
140. Huh YM, Jun Yw, Song HT, Kim S, Choi Js, Lee JH, Yoon S, Kim KS, Shin JS, Suh JS, Cheon J. In Vivo Magnetic Resonance Detection of Cancer by Using Multifunctional Magnetic Nanocrystals. Journal of the American Chemical Society 2005; 127: 12387-91.
141. Chen ZP, Zhang Y, Zhang S, Xia JG, Liu JW, Xu K, Gu N. Preparation and characterization of water-soluble monodisperse magnetic iron oxide nanoparticles via surface doubleexchange with DMSA. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2008; 316: 210-6.
142. Cao JQ, Wang YX, Yu JF, Xia JY, Zhang CF, Yin DZ, Häfeli, Urs O. Preparation and radiolabeling of surface-modified magnetic nanoparticles with rhenium-188 for magnetic targeted radiotherapy. Journal of Magnetism and Magnetic Materials 2004; 277: 165-74.
143. Daou TJ, Pourroy G, Greneche JM, Bertin A, Felder-Flesch D, Begin-Colin S. Water soluble dendronized iron oxide nanoparticles. Dalton Trans 2009: 4442-9.
144. Whitehead RA, Chagnon MS, Groman EV, Josephson L. Magnetic particles for use in separations, US Patent 4,695,392, 1987.
145. Arkles B. Tailoring surfaces with silanes. Chem Tech 1977; 7: 766.
146. Brandriss S, Margel S. Synthesis and characterization of self-assembled hydrophobic monolayer coatings on silica colloids. Langmuir 1993; 9: 1232-40.
147. Zablotskaya A, Segal I, Maiorov M, Zablotsky D, Mishnev A, Lukevics E, Shestakova I, Domracheva I. Synthesis and characterization of nanoparticles with an iron oxide magnetic core and a biologically active trialkylsilylated aliphatic alkanolamine shell. Journal of Magnetism and Magnetic Materials 2007; 311: 135-9.
148. Sun EY, Josephson L, Weissleder R. Clickable Nanoparticles for Targeted Imaging. Molecular Imaging 2006; 5: 1535-3508.
149. Shukoor MI, Natalio F, Therese HA, Tahir MN, Ksenofontov V, Panthofer M, et al. Fabrication of a Silica Coating on Magnetic γ-Fe2O3 Nanoparticles by an Immobilized Enzyme. Chemistry of Materials 2008; 20: 3567-73.
150. Martin A, Hickey J, Ablack A, Lewis J, Luyt L, Gillies E. Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells. Journal of Nanoparticle Research 2010; 12: 1599-608.
151. Widder KJ, Senyei AE, Ranney DF. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. Advances in Pharmacology and Chemotherapy 1979; 16: 213-71.
152. Devineni D, Blanton CD, Gallo JM. Preparation and in vitro Evaluation of Magnetic Microsphere-Methotrexate Conjugate Drug Delivery Systems. Bioconjugate Chemistry 1995; 6: 203-10.
153. Febvay S, Marini DM, Belcher AM, Clapham DE. Targeted Cytosolic Delivery of Cell-Impermeable Compounds by Nanoparticle-Mediated, Light-Triggered Endosome Disruption. Nano Letters 2010; 10: 2211-9.
154. Gao W, Chan JM, Farokhzad OC. pHResponsive Nanoparticles for Drug Delivery. Molecular Pharmaceutics 2010; 7: 1913-20.
155. Hammond PT. Virtual Issue on Nanomaterials for Drug Delivery. ACS Nano 2011; 5: 681-4.
156. Hu SH, Liu TY, Huang HY, Liu DM, Chen SY. Magnetic-Sensitive Silica Nanospheres for Controlled Drug Release. Langmuir 2007; 24: 239-44.
157. Jin Q, Mitschang F, Agarwal S. Biocompatible Drug Delivery System for Photo-Triggered Controlled Release of 5-Fluorouracil. Biomacromolecules 2011; 12: 3684-91.
158. Kamaly N, Kalber T, Thanou M, Bell JD, Miller AD. Folate Receptor Targeted Bimodal Liposomes for Tumor Magnetic Resonance Imaging. Bioconjugate Chemistry 2009; 20: 648-55.
159. Kang H, Trondoli AC, Zhu G, Chen Y, Chang YJ, Liu H, Huang YF, Zhang X, Tan W. Near-Infrared Light-Responsive Core-Shell Nanogels for Targeted Drug Delivery. ACS Nano 2011; 5: 5094-9.
160. Park J, Gao W, Whiston R, Strom TB, Metcalfe S, Fahmy TM. Modulation of CD4+ T Lymphocyte Lineage Outcomes with Targeted, Nanoparticle-Mediated Cytokine Delivery. Molecular Pharmaceutics 2010; 8: 143-52.
161. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications. Nano Letters 2010; 10: 3223-30.
162. Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation. Accounts of Chemical Research 2011; 44: 1123-34.
163. Sigot V, Arndt-Jovin DJ, Jovin TM. Targeted Cellular Delivery of Quantum Dots Loaded on and in Biotinylated Liposomes. Bioconjugate Chemistry 2010; 21: 1465-72.
164. Singh A, Dilnawaz F, Mewar S, Sharma U, Jagannathan NR, Sahoo SK. Composite Polymeric Magnetic Nanoparticles for Co-Delivery of Hydrophobic and Hydrophilic Anticancer Drugs and MRI Imaging for Cancer Therapy. ACS Applied Materials & Interfaces 2011; 3: 842-56.
165. Singh P, Gupta U, Asthana A, Jain NK. Folate and Folate-PEG-PAMAM Dendrimers: Synthesis, Characterization, and Targeted Anticancer Drug Delivery Potential in Tumor Bearing Mice. Bioconjugate Chemistry 2008; 19: 2239-52.
166. Yu X, Pishko MV. Nanoparticle-Based Biocompatible and Targeted Drug Delivery: Characterization and in Vitro Studies. Biomacromolecules 2011; 12: 3205-12.
167. Zeng F, Lee H, Allen C. Epidermal Growth Factor-Conjugated Poly(ethylene glycol)-block-Poly(delta-valerolactone) Copolymer Micelles for Targeted Delivery of Chemotherapeutics. Bioconjugate Chemistry 2006; 17: 399-409.
168. Zhu Y, Fang Y, Kaskel S. Folate-Conjugated Fe3O4@SiO2 Hollow Mesoporous Spheres for Targeted Anticancer Drug Delivery. The Journal of Physical
169. Zou P, Yu Y, Wang YA, Zhong Y, Welton A, Galban C, Wang S, Sun D. Superparamagnetic Iron Oxide Nanotheranostics for Targeted Cancer Cell Imaging and pH-Dependent Intracellular Drug Release. Molecular Pharmaceutics 2010; 7: 1974-84.
170. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 2006; 107: 459-66.
171. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews 2002; 54: 631-51.
172. Gruttner C, Muller K, Teller J, Westphal F, Foreman A, Ivkov R. Synthesis and antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for alternating magnetic field cancer therapy. Journal of Magnetism and Magnetic Materials 2007; 311: 181-6.
173. Pantic I. Magnetic nanoparticles in cancer diagnosis and treatment: novel approaches. Reviews on Advanced Materials Science 2010; 26: 67-73.
174. Creixell M, Herrera AP, Ayala V, Latorre-Esteves M, Perez-Torres M, Torres-Lugo M, Rinaldi C. Preparation of epidermal growth factor (EGF) conjugated iron oxide nanoparticles and their internalization into colon cancer cells. Journal of Magnetism and Magnetic Materials 2010; 322: 2244-50.
175. Dilnawaz F, Singh A, Mohanty C, Sahoo SK. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010; 31: 3694-706.
176. Zhou J, Leuschner C, Kumar C, Hormes JF, Soboyejo WO. Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastases. Biomaterials 2006; 27: 2001-8.
177. Mahmoudi M, Shokrgozar MA, Simchi A, Imani M, Milani AS, Stroeve P, Vali H, Hafeli UO, Bonakdar S. Multiphysics flow modeling and in vitro toxicity of iron oxide nanoparticles coated with poly(vinyl alcohol). Journal of Physical Chemistry C 2009; 113):2322-31.
178. Gao J, Liang G, Cheung JS, Pan Y, Kuang Y, Zhao F, Zhang B, Zhang X, Wu EX, Xu B. Multifunctional Yolk-Shell Nanoparticles: A Potential MRI Contrast and Anticancer Agent. Journal of the American Chemical Society 2008; 130: 11828-33.
179. Jin Y, Jia C, Huang SW, O'Donnell M, Gao X. Multifunctional nanoparticles as coupled contrast agents. Nat Commun 2010; 1: 41.
180. Amiri H, Mahmoudi M, Lascialfari A. Superparamagnetic colloidal nanocrystal clusters coated with polyethylene glycol fumarate: A possible novel theranostic agent. Nanoscale 2011; 3: 1022-30.
181. Lubbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D. Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer Research 1996; 56: 4694-701.
182. Lubbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, Matthias M, Dörken B, Herrmann F, Gürtler R, Hohenberger P, Haas N, Sohr R, Sander B, Lemke AJ, Ohlendorf D, Huhnt W, Huhn D. Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Research 1996; 56: 4686-93.
183. Koo H, Huh MS, Sun IC, Yuk SH, Choi K, Kim K, Kwon IC. In Vivo Targeted Delivery of Nanoparticles for Theranosis. Accounts of Chemical Research 2011; 44: 1018-28.
184. Lee JE, Lee N, Kim T, Kim J, Hyeon T. Multifunctional Mesoporous Silica Nanocomposite Nanoparticles for Theranostic Applications. Accounts of Chemical Research 2011; 44: 893-902.
185. Foy SP, Manthe RL, Foy ST, Dimitrijevic S, Krishnamurthy N, Labhasetwar V. Optical Imaging and Magnetic Field Targeting of Magnetic Nanoparticles in Tumors. ACS Nano 2010; 4: 5217-24.
186. He X, Na MH, Kim JS, Lee GY, Park JY, Hoffman AS, Nam JO, Han SE, Sim GY, Oh YK, Kim IS, Lee BH. A Novel Peptide Probe for Imaging and Targeted Delivery of Liposomal Doxorubicin to Lung Tumor. Molecular Pharmaceutics 2011; 8: 430-8.
187. Hultman KL, Raffo AJ, Grzenda AL, Harris PE, Brown TR, O'Brien S. Magnetic Resonance Imaging of Major Histocompatibility Class II Expression in the Renal Medulla Using Immunotargeted Superparamagnetic Iron Oxide Nanoparticles. ACS Nano 2008; 2: 477-84.
188. Li C, Penet MF, Wildes F, Takagi T, Chen Z, Winnard PT, Artemov D, Bhujwalla ZM. Nanoplex Delivery of siRNA and Prodrug Enzyme for Multimodality Image-Guided Molecular Pathway Targeted Cancer Therapy. ACS Nano 2010; 4: 6707-16.
189. Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, Fleischmann A, Vermathen P, Studer UE. Combined Ultrasmall Superparamagnetic Particles of Iron Oxide-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging Reliably Detect Pelvic Lymph Node Metastases in Normal-Sized Nodes of Bladder and Prostate Cancer Patients. European Urology 2009; 55: 761-9.
190. Qiang Y, Antony J, Sharma A, Nutting J, Sikes D, Meyer D. Iron/iron oxide core-shell nanoclusters for biomedical applications. Journal of Nanoparticle Research 2006; 8: 489-96.
191. Widder KJ, Morris RM, Howard DP, Senyei AE. Tumor remission in Yoshida sarcoma-bearing rats by selective targeting of magnetic albumin microspheres containing doxorubicin. Proceedings of the National Academy of Sciences of the United States of America 1981; 78: 579-81.
192. Widder KJ, Morris RM, Poore GA, Howard DP, Senyei AE. Selective targeting of magnetic albumin microspheres containing lowdose doxorubicin: total remission in Yoshida sarcoma-bearing rats. European Journal of Cancer and Clinical Oncology 1983; 19: 135-9.
193. Senyei AE, Reich SD, Gonczy C, Widder KJ. In vivo kinetics of magnetically targeted low-dose doxorubicin. Journal of Pharmaceutical Sciences 1981; 70: 39-41.
194. Goodwin S, Peterson C, Hoh C, Bittner C. Targeting and retention of magnetic targeted carriers (MTCs) enhancing intra-arterial chemotherapy. Journal of Magnetism and Magnetic Meterials 1999; 194: 132-9.
195. Goodwin SC, Bittner CA, Peterson CL, Wong G. Single-dose toxicity study of hepatic intraarterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. Toxicological Sciences 2001; 60: 177-83.
196. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Andreas S Lübbe. Locoregional cancer treatment with magnetic drug targeting. Cancer Research 2000; 60: 6641-8.
197. Lubbe AS, Bergemann C, Brock J, McClure DG. Physiological aspects in magnetic drugtargeting. Journal of Magnetism and Magnetic Meterials 1999; 194: 149-55.
198. Pulfer SK, Gallo JM. Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. Journal of Drug Targeting 1998; 6: 215-27.
199. Pulfer SK, Ciccotto SL, Gallo JM. Distribution of small magnetic particles in brain tumorbearing rats. Journal of Neuro-Oncology 1999; 41: 99-105.
200. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters. International Journal of Oncology 2000; 17: 309-15.
201. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. International Journal of Oncology 2001; 18: 121-5.
202. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. Journal of Physics D: Applied Physics 2003; 36: R167-R81.
203. Laurent S, Dutz S, Häfeli UO, Mahmoudi M. Magnetic fluid hyperthermia: Focus on superparamagnetic iron oxide nanoparticles. Advances in Colloid and Interface Science 2011; 166: 8-23.
204. Gubin SP, Koksharov YA, Khomutov GB, Yurkov GY. Magnetic nanoparticles: preparation, structure and properties. Russian Chem Reviews 2005; 74: 489-520
205. Chan DCF, Kirpotin DB, Bunn PA. Synthesis and evaluation of colloidal magnetic ironoxides for the sitespecific radiofrequencyinduced hyperthermia of cancer. Journal of Magnetism and Magnetic Materials 1993; 122: 374-8.
206. Jordan A, Wust P, Fahling H, John W, Hinz A, Felix R. Inductive heating of ferrimagnetic particles and magnetic fluids: Physical evaluation of their potential for hyperthermia. International Journal of Hyperthermia 1993; 9: 51-68.
207. Jordan A, Scholz R, Wust P, Schirra H, Thomas Schiestel, Schmidt H, Felix R. Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro. Journal of Magnetism and Magnetic Materials 1999; 194: 185-96.
208. Moroz P, Jones SK, Gray BN. Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia 2002; 18: 267-84.
209. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. Journal of Neuro-Oncology 2011; 103: 317-24.
210. Hergt R, Andra W, D'Ambly CG, Hilger I, Kaiser WA, Richter U, Schmidt, HG. Physical limits of hyperthermia using magnetite fine particles. IEEE Transactions on Magnetics 1998; 34: 3745-3754.
211. Dudeck O, Bogusiewicz K, Pinkernelle J, Gaffke G, Pech M, Wieners G, Bruhn H, Jordan A, Ricke J. Local arterial infusion of superparamagnetic iron oxide particles in hepatocellular carcinoma: A feasibility and 3.0 T MRI study. Investigative Radiology 2006; 41: 527-35.
212. Johannsen M, Gneveckow U, Eckelt L, Feussner A, Waldfner N, Scholz R, Deger S, Wust P, Loening SA, Jordan A. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial technique. International Journal of Hyperthermia 2005; 21: 637-47.
213. Johannsen M, Gneveckow U, Taymoorian K, Cho CH, Thiesen B, Scholz R, Waldöfner N, Loening SA, Wust P, Jordan A. Thermal therapy of prostate cancer using magnetic nanoparticles. Actas Urol Esp 2007; 31: 660-7.
214. Johannsen M, Gneveckow U, Taymoorian K, Thiesen B, Waldofner N, Scholz R, Jung K, Jordan A, Wust P, Loening SA. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial. International Journal of Hyperthermia 2007; 23: 315-23.
215. Johannsen M, Gneveckow U, Thiesen B, Taymoorian K, Cho CH, Waldöfner N, Scholz R, Jordan A, Loening SA, Wust P. Thermotherapy of Prostate Cancer Using Magnetic Nanoparticles: Feasibility, Imaging, and Three-Dimensional Temperature Distribution. European Urology 2007; 52: 1653-62.
216. Johannsen M, Thiesen B, Gneveckow U, Taymoorian K, Waldufner N, Scholz R, Deger S, Jung K, Loening SA, Jordan A. Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer. Prostate 2006; 66: 97-104.
217. Johannsen M, Thiesen B, Jordan A, Taymoorian K, Gneveckow U, Waldöfner N, Scholz R, Koch M, Lein M, Jung K, Loening SA. Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. Prostate 2005; 64: 283-92.
218. ® Nanotherapy: With tumor-specific nanoparticles against cancer. VDI Berichte 2005: 111-6.
219. Jordan A, Maier-Hauff K. Magnetic nanoparticles for intracranial thermotherapy. Journal of Nanoscience and Nanotechnology 2007; 7: 4604-6.
220. Jordan A, Maier-Hauff K, Wust P, Rau B, Johannsen M. Thermotherapy using magnetic nanoparticles. Thermotherapie mit magnetischen nanopartikeln 2007; 13: 894-902.
221. Jordan A, Scholz R, Maier-Hauff K, van Landeghem FKH, Waldoefner N, Teichgraeber U, Pinkernelle J, Bruhn H, Neumann F, Thiesen B, von Deimling A, Felix R. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. Journal of Neuro-Oncology 2006; 78: 7-14.
222. Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, Feussner A, von Deimling A, Waldoefner N, Felix R, Jordan A. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme. Journal of Neuro-Oncology 2007; 81: 53-60.
223. Morgul MH, Raschzok N, Schwartlander R, Vondran FW, Michel R, Stelter L, Pinkernelle J, Jordan A, Teichgraber U, Sauer IM. Tracking of primary human hepatocytes with clinical MRI: Initial results with Tat-peptide modified superparamagnetic iron oxide particles. International Journal of Artificial Organs 2008; 31: 252-7.
224. Thiesen B, Jordan A. Clinical applications of magnetic nanoparticles for hyperthermia. International Journal of Hyperthermia 2008; 24: 467-74.
225. Wust P, Gneveckow U, Johannsen M, Buhmer D, Henkel T, Kahmann F, Sehouli J, Felix R, Ricke J, Jordan A. Magnetic nanoparticles for interstitial thermotherapy-Feasibility, tolerance and achieved temperatures. International Journal of Hyperthermia 2006; 22: 673-85.
226. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. Journal of Neuro-Oncology 2011; 103: 317-24.
227. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. Journal of Neuro-Oncology 2011; 103: 317-24.
228. Johannsen M, Thiesen B, Wust P, Jordan A. Magnetic nanoparticle hyperthermia for prostate cancer. International Journal of Hyperthermia 2010; 26: 790-5.
229. Hergt R, Dutz S. Magnetic particle hyperthermia-biophysical limitations of a visionary tumour therapy. Journal of Magnetism and Magnetic Materials 2007; 311: 187-92.
230. Hayashi K, Ono K, Suzuki H, Sawada M, Moriya M, Sakamoto W, Yogo T. High-frequency, magnetic-field-responsive drug release from magnetic nanoparticle/organic hybrid based on hyperthermic effect. ACS Appl Mater Interfaces 2010; 2: 1903-11.
231. Si HY, Li DP, Wang TM, Zhang HL, Ren FY, Xu ZG, Zhao YY. Improving the anti-tumor effect of genistein with a biocompatible superparamagnetic drug delivery system. J Nanosci Nanotechnol 2010; 10: 2325-31.
232. Cedervall T, Lynch I, Lindman S, Berggård T, Thulin E, Nilsson H, Dawson KA, Linse S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proceedings of the National Academy of Sciences 2007; 104: 2050-5.
233. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proceedings of the National Academy of Sciences 2008; 105: 14265-70.
234. Cedervall T, Lynch I, Foy M, Berggård T, Donnelly SC, Cagney G, Linse S, Dawson KA. Detailed Identification of Plasma Proteins Adsorbed on Copolymer Nanoparticles. Angewandte Chemie 2007; 119: 5856-8.
235. Mahmoudi M, Shokrgozar MA, Sardari S, Moghadam MK, Vali H, Laurent S, Stroeve P. Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles. Nanoscale 2011; 3: 1127-38.
236. Mahmoudi M, Azadmanesh K, Shokrgozar MA, Journeay WS, Laurent S. Effect of nanoparticles on the cell life cycle. Chemical Reviews 2011; 111: 3407-32.
237. Mahmoudi M, Lynch I, Ejtehadi MR, Monopoli MP, Bombelli FB, Laurent S. Proteinnanoparticle interactions: Opportunities and challenges. Chemical Reviews 2011; 111: 5610-37.